期刊文献+

肿瘤PET药物的现状和展望 被引量:14

Prospect and Status of PET Radiopharmaceuticals in Oncology
下载PDF
导出
摘要 随着正电子发射计算机断层显像技术(PET)的研发,PET药物在肿瘤科学研究及临床应用中具有越来越重要的作用。本文在肿瘤代谢显像、肿瘤细胞凋亡显像、反义显像、受体显像及基因表达监测等方面集中介绍肿瘤PET药物的进展情况及其发展前景。 With the research and development of the PET techniques, the PET radiopharma- ceuticals in oncology has played more and more important role in the tumor science study and clinical application. In this paper, the development of the tumor positron radiopharmaceuticals, including the tumor metabolic imaging, tumor cell apoptotic imaging, antisense imaging, receptor imaging and monitoring of gene expression is described.
作者 王荣福
出处 《核化学与放射化学》 EI CAS CSCD 北大核心 2006年第2期65-71,共7页 Journal of Nuclear and Radiochemistry
关键词 PET药物 正电子发射计算机断层显像 核医学 代谢显像 基因显像 肿瘤 PET radiopharmaceutical positron emission tomography nuclear medicine metabolic imaging gene imaging neoplasms
  • 相关文献

参考文献28

二级参考文献99

  • 1张剑英,朱霖.^(99)Tc^m标记的乏氧组织显像剂[J].中华核医学杂志,2003,23(6):377-380. 被引量:8
  • 2Boerman O C, Oyen W J G, Corstens F H M. Between the scylla and charybdis of peptide radionuclide therapy:hitting the tumor and saving the kidney[J]. Eur J Nucl Med, 2001, 28:1447-1449.
  • 3Forssell-Aronsson E, Bernhardt P, Nilsson O, et al. Biodistribution data from 100 patients iv. injected with 111In-DTPA-D-pheloctreotide [J]. Acta Oncol, 2004, 43(5): 436-442.
  • 4Bushnell D, Menda Y, O' Dorisio T, et al. Effect of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-octreotide (SMT487[Octreo TherTM])treatment[J]. Cancer Biother Radiopharm,2004, 19(1): 35-41.
  • 5Pauwels S, Barone R, Walrand S, et al. Practical dosimetry of peptide receptor radionuclide therapy with 90Y-labeled somatostatin analogs[J]. J Nucl Med, 2005, 46(1 suppl): 92S-98S.
  • 6Moll S, Nickeleit V, Mueller-Brand J, et al. A new cause of renal thrombotic microangiopathy: Yttrium-90-DOTATOC internal radiotherapy[J]. Am J kidney Dis, 2001,37(4): 847-851.
  • 7Bodei L, Cremonesi M, Zoboli S, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion, a phase Ⅰ study[J]. Eur J Nucl Med Mol Imaging, 2003,30(2): 207-216.
  • 8Rolleman E J, Valkema R, de Jong M, et al. Safe and effective inhibition of renal uptake of radiolabelled octreotidc by a combination of lysine and arginine[J]. Eur J Nucl Med Mol Imaging, 2003, 30(1):9-15.
  • 9Barone R, Pauwels S, De Camps J, et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogs[J]. Nephrol Dial Transplant, 2004, 19(9): 2275-2281.
  • 10Barone R, Borson-Chazot F, Valkema R, et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevence of kidney volume and dose rate in finding a dose-effect relationship [J]. J Nucl Med, 2005, 46(lsuppl): 99s-106s.

共引文献49

同被引文献159

引证文献14

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部